Summary:
The study is designed to evaluate several doses of Met DR (600 to 1500 mg once daily in the morning [qAM]) compared to placebo. A single-blind reference treatment of 2000 mg metformin immediate-release (Met IR) per day administered as equal divided doses (1000 mg Met IR BID) will also be included.
Qualified Participants Must:
• Be 25 years of age or older at Visit 1 (Screening)
•
Have Type 2 Diabetes and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.